Monica Forbes
Corporate Officer/Principal at APOGEE THERAPEUTICS, INC.
Net worth: 57 392 $ as of 2024-03-30
Profile
Monica Forbes is a Senior Vice President-Finance at Apogee Therapeutics, Inc. She was previously the Chief Financial Officer & Vice President at Orexigen Therapeutics, Inc. from 2014 to 2018, and at Nalpropion Pharmaceuticals, Inc. from 2018 to 2019.
From 2019 to present, she held the position of Chief Financial Officer & Vice President at Sesen Bio, Inc. Ms. Forbes completed her undergraduate degree at San Diego State University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-03-01 | 25,283 ( 0.06% ) | 57 392 $ | 2024-03-30 |
Monica Forbes active positions
| Companies | Position | Start |
|---|---|---|
| APOGEE THERAPEUTICS, INC. | Corporate Officer/Principal | 2023-04-30 |
Former positions of Monica Forbes
| Companies | Position | End |
|---|---|---|
| CARISMA THERAPEUTICS, INC. | Director of Finance/CFO | 2023-03-06 |
Nalpropion Pharmaceuticals, Inc.
 Nalpropion Pharmaceuticals, Inc. Managed Health CareHealth Services Nalpropion Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the treatment of weight loss. Its products include CONTRAVE, analtrexone HCl & bupropion HCl extended release and Mysimba, a naltrexone HCl/ bupropion HCl prolonged release. The company is headquartered in Morristown, NJ. | Director of Finance/CFO | 2019-03-31 |
| OREXIGEN THERAPEUTICS, INC. | Director of Finance/CFO | 2018-07-26 |
Training of Monica Forbes
| San Diego State University | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| APOGEE THERAPEUTICS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Orexigen Therapeutics, Inc.
 Orexigen Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Orexigen Therapeutics, Inc. is a biopharmaceutical company, which focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its primary activities include recruiting personnel, conducting research and development, including clinical trials, raising capital, and preparing for the marketing and commercialization of its product, contrave. The company was founded by Eckard Weber in September 2002 and is headquartered in La Jolla, CA. | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Sesen Bio, Inc. is a late-stage clinical company, which engages in the development of targeted fusion protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver, and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Nalpropion Pharmaceuticals, Inc.
Nalpropion Pharmaceuticals, Inc. Managed Health CareHealth Services Nalpropion Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the treatment of weight loss. Its products include CONTRAVE, analtrexone HCl & bupropion HCl extended release and Mysimba, a naltrexone HCl/ bupropion HCl prolonged release. The company is headquartered in Morristown, NJ. | Health Services |
- Stock Market
- Insiders
- Monica Forbes
